Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes

Journal of the American College of Cardiology

Volumn 36, Issue 5, 2000, Pages 1514-1519

  Cox, Dermot ^a   Smith, Richard ^a   Quinn, Martin ^a   Theroux, Pierre ^b   Crean, Peter ^c   Fitzgerald, Desmond J ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b MONTREAL HEART INSTITUTE   (Canada)

^c ST JAMES S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CD63 ANTIGEN; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; ORBOFIBAN; THROMBIN RECEPTOR ACTIVATING PEPTIDE;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CLINICAL TRIAL; DRUG EFFECT; DRUG SCREENING; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION;

ACUTE DISEASE; AGED; ALANINE; ANGINA, UNSTABLE; FEMALE; HUMANS; MALE; MYOCARDIAL INFARCTION; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PYRROLIDINES;

EID: 0034332785     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(00)00919-0     Document Type: Article

References (31)

1. The pharmacology of the integrins
2. The therapeutic use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes
3. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease
4. Platelet activation in unstable coronary disease
5. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction
6. Unstable angina with fatal outcome: Dynamic coronary thrombosis leading to infarction and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion
7. Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death
8. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndrome (OPUS-TIMI 16) trial
9. 3 and platelet function
10. A sequence within the cytoplasmic tail of GPIIb independently activates platelet aggregation and thromboxane synthesis
11. 3
12. Bidirectional signaling between the cytoskeleton and integrins
13. 2+ signaling
14. 3) inhibitors
15. 3 (platelet GPIIb/IIIa)
16. Pentamidine: A specific, non-peptide GPIIb/IIIa antagonist
17. Quantifying GPIIb/IIIa receptor binding using two monoclonal antibodies. Discriminating abciximab and small molecular weight antagonists
18. Cellular distribution of CD63 antigen in platelets and in three megakaryocytic cell lines
19. Laminin SIKVAV peptide induction of monocyte/macrophage prostaglandin E2 and matrix metalloproteinases
20. Mechanical stressing of integrin receptors induces enhanced tyrosine phosphorylation of cytoskeletally anchored proteins
21. 2 synthesis
22. 3
23. Selective inhibition of integrin function by antibodies specific for ligand-occupied receptor conformers
24. 3 (glycoprotein IIb-IIIa) alter receptor affinity, specificity, and function
25. Soluble P-selectin as parameter for platelet activation during storage
26. Glycoprotein IIb/IIIa antagonists induce apoptosis in rat cardiomyocytes by caspase-3 activation
27. Platelet activation in patients after an acute coronary syndrome: Results from the TIMI-12 trial. Thrombolysis in Myocardial Infarction
28. Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: An OPUS-TIMI-16 substudy. Orbofiban in Patients with Unstable coronary syndromes. Thrombolysis In Myocardial Infarction
29. Platelet activation as a potential mechanism of GP IIb/IIIa inhibitor-induced thrombocytopenia
30. Variable responses to inhibition of fibrinogen binding induced by tirofiban and eptifibatide in blood from healthy subjects
31. 2 formation during coronary thrombolysis